An international research consortium led by UC San Francisco scientists has shown significant differences between the gut bacteria profiles,
of multiple sclerosis (MS) patients and healthy individuals, as well as between MS patients receiving different drug treatments.
The group also uncovered novel mechanisms by which these bacteria may potentially influence disease development and treatment response.
As of late, researchers have progressively made associations between gastrointestinal microscopic organisms and various sicknesses.
You may think that it is only gut related diseases but you're wrong; other diseases include
diabetes and arthritis.
The field of microbiome studies allowed scientists to get a detailed picture of what bacteria are present in samples of stool, blood, mucosal tissue, and skin.
The greater part of the exploratory proof proposing a connection between stomach microscopic organisms and MS had come from research in mice.
Studies in humans had offered inconsistent results-;in part because of smaller numbers of participant and some environmental effects
Sergio Baranzini is the lead author on the new study. And he says "We were surprised by the number of species that were differentially present in MS when compared to controls."